Edition:
United States

Eiger BioPharmaceuticals Inc (EIGR.OQ)

EIGR.OQ on NASDAQ Stock Exchange Global Market

12.55USD
2:54pm EST
Change (% chg)

$0.20 (+1.62%)
Prev Close
$12.35
Open
$12.35
Day's High
$12.70
Day's Low
$12.35
Volume
5,939
Avg. Vol
15,949
52-wk High
$13.95
52-wk Low
$6.15

Select another date:

Mon, Dec 11 2017

BRIEF-Eiger Biopharma Files For Mixed Shelf Of Up To $125 Mln

* EIGER BIOPHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $125 MILLION - SEC FILING Source text: (http://bit.ly/2nUkpvR) Further company coverage:

BRIEF-‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​

* ‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​ as of Oct 31 - SEC filing Source text: (http://bit.ly/2mbmToK) Further company coverage:

BRIEF-Eiger Biopharmaceuticals reports Q3 loss per share $1.10

* Eiger Biopharmaceuticals reports third quarter 2017 financial results

BRIEF-Eiger Biopharmaceuticals closes public offering

* Eiger Biopharmaceuticals announces closing of public offering of common stock and exercise in full of underwriter's option to purchase additional shares Source text for Eikon: Further company coverage:

BRIEF-EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

* EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Eiger BioPharmaceuticals announces proposed public offering of common stock

* Eiger BioPharmaceuticals announces proposed public offering of common stock

BRIEF-Eiger appoints Evan Loh to its Board of Directors

* Eiger announces appointment of biopharmaceutical industry veteran Evan Loh, MD to its Board of Directors Source text for Eikon: Further company coverage:

BRIEF-Sphera Funds Management reports 5.35 pct passive stake in Eiger Biopharmaceuticals

* Sphera Funds Management Ltd reports a 5.35 percent passive stake in Eiger Biopharmaceuticals Inc as of August 17, 2017 - SEC Filing​ Source text: (http://bit.ly/2wBB2yX) Further company coverage:

BRIEF-Eiger Biopharmaceuticals Q2 loss per share $1.33

* Eiger Biopharmaceuticals reports second quarter 2017 financial results

BRIEF-Eiger announces FDA fast track designation granted for pegylated interferon lambda

* Eiger announces fda fast track designation granted for pegylated interferon lambda in hepatitis delta virus infection Source text for Eikon: Further company coverage:

Select another date: